An Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of A Single Dose Of Aprepitant, A Moderate CYP3A Inhibitor On Bosutinib Administered Orally To Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2016
Price : $35 *
At a glance
- Drugs Bosutinib (Primary) ; Aprepitant
- Indications Chronic myeloid leukaemia
- Focus Pharmacokinetics
- Sponsors Pfizer
- 07 Oct 2016 Results published in the European Journal of Clinical Pharmacology
- 23 Jun 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Apr 2014 Planned End Date changed from 1 Apr 2014 to 1 Jun 2014 according to ClinicalTrials.gov record.